![](/wp-content/themes/basic-child/images/print.png)
Sudden Cardiac Death: What to Know?
![heart-attack-7479253_1280 heart-attack-7479253_1280](https://lymediseaseassociation.org/wp-content/uploads/2023/12/heart-attack-7479253_1280.jpg)
The People’s Pharmacy, “Show 1365: Revealing the Secrets of Sudden Cardiac Death” featured guest, Dr. Zian Tseng. Dr. Tseng discusses the differences between two heart conditions, heart attack and cardiac arrest.
The People’s Pharmacy, “Show 1365: Revealing the Secrets of Sudden Cardiac Death” featured guest, Dr. Zian Tseng. Dr. Tseng discusses the differences between two heart conditions, heart attack and cardiac arrest.
Fox News, Melissa Rudy, 12.10.2023, reports on “Deadly Rocky Mountain spotted fever outbreak in California likely came from Mexico, CDC says.” The Centers for Disease Control and Prevention (CDC) issued a health advisory on 12.08.2023 advising of an outbreak of Rocky Mountain spotted fever (RMSF) southern California which has hospitalized five people and resulted in three deaths between late July and December 2023.
Science by the Slice, 12.06.2023, released “Tick Talk: How Researchers Are Using Online Search Behavior to Understand Tick Prevention.” In the episode of this podcast, Dr. Lauri Baker and Cheng-Xian Yang share their research on ticks and tick-borne diseases, focusing on public perceptions and behaviors related to these issues. The conversation delves into the reasons people should be concerned about ticks, particularly highlighting the risks associated with […]
JAMA Network, 12.08.2023, published, “State-Regulated Psychedelics on a Collision Course With FDA.” In this online viewpoint article, Mason Marks, MD, JD, discusses that the Food and Drug Administration (FDA) may soon approve psychedelics for treating conditions of depression, posttraumatic stress disorder, and other indications, but that psychedelics are currently considered Schedule I controlled substances with high potential for abuse; and are currently not accepted for medical use.
The People’s Pharmacy, Joe Graedon, (11.28.2023) reports “New Concerns About Gabapentin and Pregabalin (Lyrica) for Nerve Pain.” Concerning data has come out of the FDA’s Adverse Event Reporting System (FAERS) regarding drugs that are regularly prescribed for nerve pain.
5 On Your Side (Bassler, H.) 11.22.2023, published “A sesame seed-sized tick is spreading across Missouri. Here’s what to know.” The article discusses the spread of various tick-borne diseases in Missouri, particularly due to the invasive Asian longhorned tick. This tick was first reported in the U.S. in 2017, but potentially present since before 2010. It has been detected across multiple states and is known for transmitting diseases like anaplasmosis, babesiosis, ehrlichiosis, […]
JAMA Network (Vordenberg, S. E.) published on 11.03.2023 an article, “Topical Nonprescription Pain Medications for Adults.” In this article post, Vordenberg talks about nonprescription pain medications that you can buy without a prescription. These medications are applied directly to the skin to relieve pain.
Topical Nonprescription Pain Medications are pain-relieving drugs that you can buy without a prescription and are applied on the skin, making them easy to use. They work by effectively treating pain from various conditions, both short-term and long-term. Since they are applied on the skin, they are less likely to cause side effects or interact with other medications compared to pills. Pain relief usually starts within a few days of using them.
Frontiers (Stewart Z., et al.) 10.24.2023, published “Crowd-sourced investigation of a potential relationship between Bartonella-associated cutaneous lesions and neuropsychiatric symptoms.” This article explores the potential relationship between Bartonella bacteria infections and psychiatric symptoms, focusing on how certain skin lesions associated with Bartonella might coincide with neuropsychiatric issues.
The Journal of Allergy and Clinical Immunology: In Practice (Ailsworth SM., et al.) 10.31.2023, published “Alpha-gal IgE Prevalence Patterns in the United States: An Investigation of 3000 Military Recruits”. This article investigates Alpha-gal syndrome (AGS), an allergy to mammalian meat, particularly associated with bites from lone star ticks (Amblyomma americanum).
JAMA (Yang, Y., et al. )10. 24. 2023 published an original investigation “Traditional Chinese Medicine Compound (Tongxinluo) and Clinical Outcomes of Patients With Acute Myocardial Infarction: The CTS-AMI Randomized Clinical Trial.” Investigators of this clinical study conducted a randomized, double-blind, placebo-controlled clinical trial of 3777 patients with acute ST-segment elevation myocardial infarction (STEMI). Patients from 124 hospitals in China presenting with STEMI between May-December 2020 were given either oral Tongxinluo or placebo within 24 hours of symptom onset. The adjunctive treatment or placebo was administered for 12 months, and positive patient outcome was observed.
LDA Doctor Referral System © Terms & Conditions and Guidelines
Save this Information for Your Records:
About LDA DOCTOR REFERRAL SYSTEM ©
Welcome to the Lyme Disease Association’s LDA Doctor Referral System ©. LDA made updates and enhancements to its prior system and has launched a new site to provide patients with information about doctors, other practitioners, testing labs, and pharmacies that are knowledgeable about chronic Lyme disease and often about many other tick-borne diseases (TBD). Many of the doctors listed are often referred to as Lyme Literate Physicians/Doctors (LLMD). Tens of thousands of patients have successfully used the prior LDA system to locate Lyme and TBD resources.
Terms & Conditions and Guidelines
Because there is a negative political climate surrounding Lyme disease, many LLMDs do not want their names posted outright on the internet. LDA has tried to balance the doctors’ wishes with patients’ need to find a doctor. This new system is a result of that compromise and therefore:
Because of the limited number of physicians treating chronic Lyme disease nationwide, some states, and in some instances, entire regions, may not have any treating physicians who follow flexible treating approaches such as those in the International Lyme & Associated Diseases Society (ILADS) Guidelines, Evidence Assessments and Guideline Recommendations in Lyme Disease: The Clinical Management of Known Tick Bites, Erythema Migrans Rashes and Persistent Disease. In the event that the LDA Doctor Referral System © contains no Lyme or TBD resource listings in a given area, the closest possible option(s) will populate based on the location entered and specaialty/ies selected. The LDA appreciates any changes in provider information that you may find and make us aware of so we can investigate.
Some providers may not specifically treat Lyme and TBD but see patients who have symptoms associated with Lyme and TBD to address those specific symptoms. Contact the provider to confirm.
It is your responsibility to contact the provider’s office to confirm the current address, directions, nature of services provided, and all other provider information before you make an appointment.
DISCLAIMER: The Lyme Disease Association, Inc. provides referrals to health care providers who treat Lyme disease, and often other TBD, as a courtesy to those seeking Lyme Literate Physicians (LLMD). However, some of the providers included do not specifically treat Lyme and TBD but see patients who have symptoms associated with Lyme and TBD to address those specific symptoms. We do not evaluate the professional competence or qualifications of health care providers on our referral list or the costs of services provided. Accordingly, the LDA neither warrants nor endorses the health care providers contained on this list nor the quality of care you will receive from those providers. We do not make recommendations, only referrals. LDA does not receive any monies from physicians to be included on this list nor does LDA provide any monies to physicians. Because of the limited number of physicians treating chronic Lyme disease nationwide, some states, and in some instances, entire regions, may not have any treating physicians who follow flexible treating approaches such as those in the International Lyme & Associated Diseases Society (ILADS) Guidelines: Evidence Assessments and Guideline Recommendations in Lyme Disease: The Clinical Management of Known Tick Bites, Erythema Migrans Rashes and Persistent Disease. In the event that the Doctor Referral System contains no Lyme or TBD resource listings in a given area, the closest possible option(s) will populate based on the zip code entered and category/ies selected. The LDA appreciates any changes in provider information that you may find and make us aware of.
LDA does not accept or reply to any comments on:
We cannot guarantee that the information provided will be timely and accurate or that physicians on the list are accepting new patients, or that they accept insurance. The selection of a physician should be made by you after careful consideration. There are two approaches in the treatment of Lyme disease. Our list contains physicians who generally follow more flexible treatment approaches than those advocated by the Infectious Diseases Society of America (IDSA). LDA is not responsible for incorrect information on the website. BEFORE DOCTOR VISIT: Please contact the physicians’ offices directly to confirm their current address, directions, and any other necessary information before scheduling an appointment. Do not rely only on the maps provided on this site. The maps on LDA’s Doctor Referral System are for informational purposes and provide an approximate locality of the listing based on the addresses we are provided with at the time of site updates. Practitioners often relocate and addresses can change. Notification of changes in listed information can be updated on our Dr. Referral Contact Form. Thank you, Lyme Disease Association, Inc. (LDA)
Subscriber information will not be shared outside of the Lyme Disease Association, Inc. nor used for donor solicitation.
The Lyme Disease Association, Inc. reserves the right to unsubscribe anyone from this service without cause.